[go: up one dir, main page]

PL2490986T3 - Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej - Google Patents

Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej

Info

Publication number
PL2490986T3
PL2490986T3 PL10825598T PL10825598T PL2490986T3 PL 2490986 T3 PL2490986 T3 PL 2490986T3 PL 10825598 T PL10825598 T PL 10825598T PL 10825598 T PL10825598 T PL 10825598T PL 2490986 T3 PL2490986 T3 PL 2490986T3
Authority
PL
Poland
Prior art keywords
systems
methods
botulinum neurotoxin
purifying non
complexed botulinum
Prior art date
Application number
PL10825598T
Other languages
English (en)
Inventor
Curtis L. Ruegg
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43879799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2490986(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of PL2490986T3 publication Critical patent/PL2490986T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL10825598T 2009-10-21 2010-10-20 Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej PL2490986T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25381009P 2009-10-21 2009-10-21
PCT/US2010/053389 WO2011050072A1 (en) 2009-10-21 2010-10-20 Methods and systems for purifying non-complexed botulinum neurotoxin
EP10825598.5A EP2490986B2 (en) 2009-10-21 2010-10-20 Methods and systems for purifying non-complexed botulinum neurotoxin

Publications (1)

Publication Number Publication Date
PL2490986T3 true PL2490986T3 (pl) 2019-03-29

Family

ID=43879799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10825598T PL2490986T3 (pl) 2009-10-21 2010-10-20 Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej

Country Status (24)

Country Link
US (5) US20120196349A1 (pl)
EP (1) EP2490986B2 (pl)
JP (1) JP5951490B2 (pl)
KR (1) KR101819129B1 (pl)
CN (2) CN104961812B (pl)
AU (1) AU2010310749B2 (pl)
BR (1) BR112012009227A2 (pl)
CA (1) CA2773396C (pl)
CO (1) CO6551670A2 (pl)
CY (1) CY1120908T1 (pl)
DK (1) DK2490986T4 (pl)
ES (1) ES2688065T5 (pl)
HR (1) HRP20181869T1 (pl)
HU (1) HUE041599T2 (pl)
IL (2) IL218532A (pl)
LT (1) LT2490986T (pl)
MX (3) MX365496B (pl)
PH (1) PH12012500549A1 (pl)
PL (1) PL2490986T3 (pl)
PT (1) PT2490986T (pl)
RS (1) RS58006B1 (pl)
SI (1) SI2490986T1 (pl)
SM (1) SMT201800487T1 (pl)
WO (1) WO2011050072A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180739T1 (hr) 2008-12-31 2018-06-29 Revance Therapeutics, Inc. Injekcijske formulacije botulinskog toksina
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
CN105658662B (zh) * 2013-07-30 2022-05-27 莫茨制药有限及两合公司 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
EP3901163A4 (en) * 2018-12-21 2022-10-05 The Research Foundation for Microbial Diseases of Osaka University PROCESS FOR PRODUCTION OF BOTULINUM TOXIN
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102516203B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 제조방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724650B1 (ko) * 2021-07-05 2024-11-01 주식회사 파마리서치바이오 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법
KR20240140863A (ko) * 2023-03-16 2024-09-24 주식회사 대웅 다중모드 크로마토그래피를 이용한 개선된 보툴리눔 독소의 정제방법
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US796419A (en) 1904-07-18 1905-08-08 Carl Halbig Doll-head.
SE303567B (pl) * 1959-02-17 1968-09-02 Behringwerke Ag
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
CA2319113A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
CA2797652C (en) * 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB2386246B (en) 2001-11-01 2005-06-29 Marconi Applied Techn Ltd Electron beam tube apparatus
US7118901B2 (en) * 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
KR100498964B1 (ko) 2003-03-05 2005-07-01 삼성전자주식회사 이동단말에서의 전자파 흡수율 제어 방법 및 장치
WO2004108750A1 (en) * 2003-06-06 2004-12-16 Avecia Limited Process for the separation of proteins
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
BRPI0417399A (pt) * 2003-12-30 2007-04-17 Bharat Biotech Int Ltd processo para preparação e purificação de proteìnas
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
PT1729821E (pt) * 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
AU2005251676B2 (en) * 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1930186A (zh) * 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
ATE430797T1 (de) * 2005-06-17 2009-05-15 Merz Pharma Gmbh & Co Kgaa Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
PT2085093E (pt) * 2006-10-27 2015-06-26 Chemo Sero Therapeut Res Inst Preparação que contém uma toxina botulínica tipo a altamente purificada derivada de um agente patogénico do botulismo infantil
CN100588706C (zh) * 2007-04-06 2010-02-10 常州千红生化制药股份有限公司 纯化弹性蛋白酶的方法
CN101687018A (zh) * 2007-06-01 2010-03-31 德国麦氏大药厂 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
HRP20180739T1 (hr) * 2008-12-31 2018-06-29 Revance Therapeutics, Inc. Injekcijske formulacije botulinskog toksina
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
US8440104B2 (en) * 2009-10-21 2013-05-14 General Electric Company Kimzeyite garnet phosphors
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
WO2013181576A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods of evaluating and making biologics
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
SG10202004337WA (en) * 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2018213710A1 (en) * 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia

Also Published As

Publication number Publication date
EP2490986A4 (en) 2013-11-13
IL218532A0 (en) 2012-07-31
CY1120908T1 (el) 2019-12-11
DK2490986T3 (en) 2018-11-05
CN102666396A (zh) 2012-09-12
EP2490986B1 (en) 2018-08-08
HK1215951A1 (zh) 2016-09-30
MX2012004703A (es) 2012-06-08
CA2773396A1 (en) 2011-04-28
JP5951490B2 (ja) 2016-07-13
KR20120099431A (ko) 2012-09-10
US20170029795A1 (en) 2017-02-02
SMT201800487T1 (it) 2019-01-11
RS58006B1 (sr) 2019-02-28
WO2011050072A1 (en) 2011-04-28
ES2688065T3 (es) 2018-10-30
US20110092682A1 (en) 2011-04-21
IL248486A0 (en) 2016-12-29
CO6551670A2 (es) 2012-10-31
LT2490986T (lt) 2018-11-26
DK2490986T4 (da) 2024-06-17
EP2490986A1 (en) 2012-08-29
PH12012500549A1 (en) 2017-08-23
PT2490986T (pt) 2018-11-13
AU2010310749A1 (en) 2012-03-29
MX365496B (es) 2019-06-05
US20200277591A1 (en) 2020-09-03
US11466262B2 (en) 2022-10-11
US9469849B2 (en) 2016-10-18
CN104961812B (zh) 2019-08-20
ES2688065T5 (es) 2024-10-04
US20120196349A1 (en) 2012-08-02
KR101819129B1 (ko) 2018-02-28
HUE041599T2 (hu) 2019-05-28
CA2773396C (en) 2020-12-15
BR112012009227A2 (pt) 2016-08-23
IL218532A (en) 2016-10-31
HRP20181869T1 (hr) 2019-01-11
MX2019006519A (es) 2019-09-18
JP2013508388A (ja) 2013-03-07
HK1175453A1 (en) 2013-07-05
SI2490986T1 (sl) 2018-12-31
US20150322419A1 (en) 2015-11-12
CN104961812A (zh) 2015-10-07
AU2010310749B2 (en) 2016-02-11
EP2490986B2 (en) 2024-04-24
CN102666396B (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
IL248486A0 (en) Methods and systems for purifying uncomposite botulinum neurotoxin
SI3252070T1 (sl) Postopek in sistem za pridobivanje botulinskega nevrotoksina
TWI365145B (en) Method and system for asisting driver
EP2497193A4 (en) SYSTEM AND METHOD FOR MOBILE INTERACTION
EP2247366A4 (en) SYSTEMS AND METHODS FOR CO2 TREATMENT
GB2520198B (en) Method and systems for media consumption
EP2475950A4 (en) SYSTEM AND METHOD FOR BALLISTIC SOLUTIONS
IL207116A0 (en) System and method for location tracking
PL2289767T3 (pl) Oparte na stabilności sposoby i układy sterowania kierowaniem
EP2395130A4 (en) METHOD AND SYSTEM FOR FACTORY OPERATION
IL215670A0 (en) Systems and methods for interrupted progam recording
ZA201200768B (en) System and method for vehicle performance control
IL214372A0 (en) Means and methods for manufacturing highly pure neurotoxin
EP2430514A4 (en) METHODS OF INTERACTING WITH INFORMATION AND MANIPULATION THEREOF AND RELATED SYSTEMS
GB0903274D0 (en) Fluoreence method and system
EP2399395A4 (en) SYSTEMS AND METHOD FOR QUICK CHANNEL SWITCHING
GB2473109B (en) System and method for near-optimal media sharing
EP2457025A4 (en) METHOD AND SYSTEMS FOR IMPROVED COMBUSTION PROCESSES
ZA201201436B (en) Method and system for polypeptide purification
GB201504199D0 (en) Method and system
TWM386534U (en) Information processing system for vehicle maintenance
ZA201201689B (en) System for determining unprocessed and partially processes neurotoxin type a
IL214218A0 (en) Systems and methods for bio-elecricity production
TWI349233B (en) Navigation system and switching mode method for navigation system
AU2009901043A0 (en) Travel system and method